The Food and Drug Administration (FDA) announced a new proposal Monday for flexible drug approval pathway treatments addressing ultrarare diseases. The FDA unveiled draft guidance on a proposed ...
Jason Mast is a general assignment reporter at STAT focused on the science behind new medicines and the systems and people that decide whether that science ever reaches patients. You can reach Jason ...
Multi-omics profiling of residual cancer burden after neoadjuvant hormonal therapy guides subtype-directed treatment in high-risk and locally advanced prostate cancer. Predictive associations between ...
FDA proposes using a well-supported mechanistic rationale plus natural history comparators to generate substantial evidence when randomized trials are infeasible for ultra-rare populations.
Compass Pathways has announced that its investigational psilocybin treatment has successfully met its primary endpoint in a second Phase 3 clinical trial moving it one step closer to FDA submission.
Arizona is changing faster than almost any state in the country. Our population continues to grow, our cities are expanding, and our communities are becoming more diverse and complex. Arizona has ...
Background Socioeconomic exposures related to anaemia in Peruvian children have been modelled assuming additive or log-additive relationships, yet such approaches overlook the fact that illness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results